Epidermal growth factor receptor (EGFR) activation contributes to pancreatic cancer etiology, yet anti-EGFR therapy offers minimal clinical benefits in patients with KRAS mutations. We report that plasminogen activator inhibitor-1 (PAI-1) derived from cancer-associated fibroblasts (CAFs) is selectively elevated in KRAS-mutant...
AbstractPurpose Clinical studies have suggested a therapeutic synergy between EGFR-TKIs and radiotherapy; however, the underlying mechanisms remain incompletely understood, particularly in tumors harboring the acquired resistance mutation EGFR T790M. Methods Using EGFR T790M-positive cell lines, patient-derived organoids (PDOs), and patient-derived...
Lung repair involves coordination of multicellular processes, including endothelial angiogenesis and epithelial repopulation. Retinoic acid (RA) signalling is crucial for lung development, homeostasis, and repair; however, the mechanisms through which RA drives repair are still unknown. It has previously been...
Epidermal growth factor receptor (EGFR) signalling plays a crucial role in renal fibrosis. We previously demonstrated that EGFR mimotope vaccination could alleviate renal fibrosis by restoring major histocompatibility complex class IB (MHC-IB) expression in renal tubular epithelial cells and promoting...
Moringa oleifera pericarp, an underutilized agro-waste, was investigated as a potential source of anticancer agents. In this study, bioassay-guided fractionation of the pericarp extract led to the identification of the ethyl acetate fraction as the most active fraction, showing notable...
ArticlesVolume 27, Issue 7p785-794July 2026Download Full Issue Download started OkAumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trialProf Ziming Li, MDa,† ∙ Prof Jie Hu, MD PhDb,c,† ∙ Prof...
AbstractBackground Non-alcoholic fatty liver disease (NAFLD) is associated with metabolic cell death (MCD), and this study aimed to dig deeper into the biomarkers associated with MCD in NAFLD, and to provide new references for the diagnosis and treatment of NAFLD....
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT® (sibeprenlimab-szsi) demonstrated statistically significant stabilization of kidney function, with evidence...
Kirsten rat sarcoma viral oncogene (KRAS) G12C inhibitors have demonstrated clinical efficacy against KRAS G12C–mutant non-small cell lung cancer (NSCLC); however, intrinsic and acquired resistance limit their therapeutic potential. Therefore, combination strategies are needed to address these limitations. While various...
Otsuka Holdings Co., Ltd TSE:4578: Otsuka Holdings Co., Ltd - Otsuka Reports Positive Phase 3 Visionary Two-Year Egfr Results For Voyxact In IganRefinitiv Sign up to read this newsJoin for freeMore news from Reuters [Additional Text]: Reuters
